- Home
- GHG vs DMAC Comparison
GHG vs DMAC Comparison
Compare GHG & DMAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GHG
- DMAC
- Stock Information
- Founded
- GHG 2004
- DMAC 2000
- Country
- GHG China
- DMAC United States
- Employees
- GHG N/A
- DMAC N/A
- Industry
- GHG Hotels/Resorts
- DMAC Biotechnology: Pharmaceutical Preparations
- Sector
- GHG Consumer Discretionary
- DMAC Health Care
- Exchange
- GHG Nasdaq
- DMAC Nasdaq
- Market Cap
- GHG 202.0M
- DMAC 178.0M
- IPO Year
- GHG 2018
- DMAC N/A
- Fundamental
- Price
- GHG $2.34
- DMAC $3.63
- Analyst Decision
- GHG
- DMAC Strong Buy
- Analyst Count
- GHG 0
- DMAC 2
- Target Price
- GHG N/A
- DMAC $8.00
- AVG Volume (30 Days)
- GHG 11.9K
- DMAC 325.9K
- Earning Date
- GHG 08-14-2025
- DMAC 08-06-2025
- Dividend Yield
- GHG 4.35%
- DMAC N/A
- EPS Growth
- GHG N/A
- DMAC N/A
- EPS
- GHG 0.15
- DMAC N/A
- Revenue
- GHG $184,055,595.00
- DMAC N/A
- Revenue This Year
- GHG $19.02
- DMAC N/A
- Revenue Next Year
- GHG $8.26
- DMAC N/A
- P/E Ratio
- GHG $16.17
- DMAC N/A
- Revenue Growth
- GHG N/A
- DMAC N/A
- 52 Week Low
- GHG $1.93
- DMAC $2.98
- 52 Week High
- GHG $3.40
- DMAC $6.82
- Technical
- Relative Strength Index (RSI)
- GHG 59.62
- DMAC 44.55
- Support Level
- GHG $1.97
- DMAC $3.48
- Resistance Level
- GHG $2.40
- DMAC $3.88
- Average True Range (ATR)
- GHG 0.11
- DMAC 0.26
- MACD
- GHG 0.03
- DMAC 0.00
- Stochastic Oscillator
- GHG 76.00
- DMAC 30.10
About GHG GreenTree Hospitality Group Ltd. American depositary shares each representing one ordinary share
GreenTree Hospitality Group Ltd is a franchised hotel operator in China as franchised and managed hotels represent almost all the hotels in its hotel network. The hotel network of the company comprised approximately 4,059 hotels with nearly 302,497 rooms in China, covering all centrally administrated municipalities and cities throughout all provinces and autonomous regions in China. The company operates its hotels under GreenTree Inns, GreenTree Eastern, Gme, Gya and VX, GreenTree Alliance, Vatica, and others. The company operates solely in China and generates all its revenue from China itself.
About DMAC DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.